Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Author(s):Hakim, J.G. | Thompson, J. | Kityo, C. | Hoppe, A. | Kambugu, A. | van Oosterhout, J.J. | Lugemwa, A. | Siika, A. | Mwebaze, R. | Mweemba, A. | Abongomera, G. | Thomason, M.J. | Easterbrook, P. | Mugyenyi, P. | Walker, A.S. | Paton, N.I. | Agweng, E. | Awio, P. | Bakeinyaga, G. | Isabirye, C. | Kabuga, U. | Kasuswa, S. | Katuramu, M. | Kiweewa, F. | Kyomugisha, H. …read more

Source:: cowley, sally a.” 7102482900 “james, william s.” 35479049300 “moore, michael d.